Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL 15 versus DAYTRANA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL 15 versus DAYTRANA.
ADDERALL 15 vs DAYTRANA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall 15 is a combination of amphetamine and dextroamphetamine, which increase synaptic concentrations of norepinephrine and dopamine by inhibiting their reuptake and promoting their release from presynaptic terminals.
Methylphenidate is a central nervous system stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their extracellular concentrations.
10-20 mg orally once daily in the morning; may increase by 5-10 mg weekly; maximum 40 mg/day.
Initial: 10 mg transdermal patch applied to hip for 9 hours daily; may titrate weekly in increments of 5 mg to a maximum of 30 mg/day.
None Documented
None Documented
Mean terminal half-life: d-amphetamine 10 h, l-amphetamine 13 h (range 9-14 h); for ADDERALL 15 (3:1 mix), effective half-life ~11 h; clinical context: dosing interval typically QD-BID.
Terminal half-life in children is approximately 5–6 hours; in adults, approximately 5 hours; wears off within 12 hours of patch removal.
Primarily renal (90% as unchanged drug and metabolites; ~30% unchanged, 40% as 4-hydroxyamphetamine and conjugates, 20% as other metabolites); minimal biliary/fecal elimination (<3%).
Renal (approx. 78% unchanged) and fecal (approx. 10%); remainder as metabolites.
Category C
Category C
CNS Stimulant
CNS Stimulant